The FAT3 antibody targets the FAT3 protein, a member of the cadherin superfamily and one of the largest protocadherins. FAT3 is encoded by the *FAT3* gene and plays critical roles in cellular adhesion, signaling, and tissue morphogenesis, particularly in the nervous system. It is involved in neuronal development, including axon guidance, synaptic connectivity, and cellular polarity, by mediating homophilic or heterophilic interactions. Dysregulation of FAT3 has been linked to cancer progression, neurodevelopmental disorders, and retinal defects.
FAT3 antibodies are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to detect FAT3 in tissue samples, cell lines, or model organisms. Researchers utilize these antibodies to explore FAT3's role in tumorigenesis, metastasis, and neuronal circuit formation. Commercial FAT3 antibodies are typically developed in hosts like rabbits or mice, often validated for specificity using knockout controls. Recent studies highlight FAT3's potential as a biomarker in cancers, such as glioblastoma and colorectal cancer, where its abnormal expression correlates with patient outcomes. However, variability in antibody performance across applications necessitates careful validation for experimental consistency.